Intellia Shares Jump After FDA Lifts Clinical Hold on Gene Therapy Trial

Intellia Therapeutics’ stock rises as the FDA clears a Phase 3 trial for its gene therapy, nexiguran ziclumeran, for a rare genetic disease.